-
Integrated Proteomic and Metabolomic prediction of Term Preeclampsia.
Bahado-Singh R, Poon LC, Yilmaz A, Syngelaki A, Turkoglu O, Kumar P, Kirma J, Allos M, Accurti V, Li J, Zhao P, Graham SF, Cool DR, Nicolaides K.
Sci Rep 2017;7:16189. pdf -
Maternal serum anti-Mallerian hormone at 11-13 weeks' gestation in the prediction of preeclampsia.
Birdir C, Fryze J, Vasiliadis H, Nicolaides KH, Poon LC.
J Matern Fetal Neonatal Med 2015;28:865-8. pdf -
Proteomic Biomarkers of Preterm Birth Risk in Women with Polycystic Ovary Syndrome (PCOS): A Systematic Review and Biomarker Database Integration.
Galazis N, Docheva N, Nicolaides KH, Atiomo W.
PLoS One 2013;8:e53801. -
Maternal serum visfatin at 11-13 weeks' gestation in preeclampsia.
Ferreira AF, Rezende JC, de Cassia C Oliveira R, Akolekar R, Nicolaides KH.
J Hum Hypertens 2013;27:261-4. -
Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11-13 Weeks?
Mastricci AL, Akolekar R, Kuppusamy R, Ahmed M, Nicolaides KH.
Fetal Diagn Ther 2011;30:53-9. -
Maternal serum visfatin at 11-13 Weeks of gestation in gestational diabetes mellitus.
Ferreira AF, Rezende JC, Vaikousi E, Akolekar R, Nicolaides KH.
Clin Chem 2011;57:609-13. -
Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11-13 weeks.
Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH.
Prenat Diagn 2011;31:75-83. -
Maternal serum ADAM12 (A disintegrin and metalloprotease) in chromosomally abnormal pregnancy at 11-13 weeks.
Poon LC, Chelemen T, Minekawa R, Frisova V, Nicolaides KH.
Am J Obstet Gynecol 2009;200:508.1-6. -
First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome.
Poon LC, Chelemen T, Granvillano O, Pandeva I, Nicolaides KH.
Obstet Gynecol 2008;112:1082-90. -
ADAM12-s in coelomic fluid and maternal serum in early pregnancy.
Makrydimas G, Sotiriadis A, Spencer K, Cowans NJ, Nicolaides KH.
Prenat Diagn 2006;26:1197-200.